MedTrace Logo

A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07044050 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-06-29

No results posted yet for this study

Summary

The goal of this clinical trial is to learn the safety of OT-C001 and decide a good dose in treating relapsed or refractory diffuse large B-cell lymphoma patients. It will also learn about the preliminary activity of OT-C001.

Participants will:

Receive a short course of chemotherapy before OT-C001 treatment. During the study treatment, participants will recieve weekly dose of OT-C001 for 3 or 6 weeks. During the study period, participants will also receive another two drugs, rituximab and IL-2, to support OT-C001 treatment.

Participants need to visit the clinic or may be hospitalized according to the study plan.

Conditions

  • Diffuse Large B-cell Lymphoma With no Other Specification

Interventions

BIOLOGICAL

allogenic natural killer cells

OT-C001 will be administered by IV infusion weekly for at least 3 doses.

Sponsors & Collaborators

  • Emercell SAS

    lead INDUSTRY

Principal Investigators

  • Alain Herrera · Emercell SAS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2026-09-30
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07044050 on ClinicalTrials.gov